Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis ; volume:23 ; number:1 ; day:30 ; month:11 ; year:2023 ; pages:1-12 ; date:12.2023
BMC cancer ; 23, Heft 1 (30.11.2023), 1-12, 12.2023
- Urheber
-
Luo, Jian
Xiao, Wanying
Hua, Fengyang
Cao, Yanqing
Wang, Dongxia
Wang, Xicheng
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-023-11318-y
- URN
-
urn:nbn:de:101:1-2024021916444014614501
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.01.2002, 05:17 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Luo, Jian
- Xiao, Wanying
- Hua, Fengyang
- Cao, Yanqing
- Wang, Dongxia
- Wang, Xicheng
- SpringerLink (Online service)
Ähnliche Objekte (12)
A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer
Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer
Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial
Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma
Preliminary evidence for endoscopic surgery combined with postoperative anti-PD-1 immunotherapy in advanced recurrent nasopharyngeal carcinoma
Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Recurrent Nasopharyngeal Carcinoma and the Role of Surgery
New T staging recommendations for recurrent nasopharyngeal carcinoma
Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma
Photodynamic therapy in the treatment of recurrent nasopharyngeal cancer
The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer
Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer
Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial
Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma
Preliminary evidence for endoscopic surgery combined with postoperative anti-PD-1 immunotherapy in advanced recurrent nasopharyngeal carcinoma
Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Recurrent Nasopharyngeal Carcinoma and the Role of Surgery
New T staging recommendations for recurrent nasopharyngeal carcinoma
Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma
Photodynamic therapy in the treatment of recurrent nasopharyngeal cancer
The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer
Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer
Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial
Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma
Preliminary evidence for endoscopic surgery combined with postoperative anti-PD-1 immunotherapy in advanced recurrent nasopharyngeal carcinoma
Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Recurrent Nasopharyngeal Carcinoma and the Role of Surgery
New T staging recommendations for recurrent nasopharyngeal carcinoma
Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma
Photodynamic therapy in the treatment of recurrent nasopharyngeal cancer